Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin Treatment of Pathological Gambling
NCT02337634Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2015
- Primary completion
- Dec 2022
- Countries
- 1
- Sponsor
- University of Chicago
- Modality
- Small Molecules
- Drugs
- silymarin
- Conditions
- gambling disorder (GD)
01
Overview
Phase 2, randomised, double-blind trial in gambling disorder (GD) comparing Placebo with Milk Thistle (2 arms). Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling at 8 weeks. Started Jan 2015; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo
Matched dosage of milk thistle daily.
Milk Thistle
Capsule form, 150mg BID to 300mg BID
03
Who it enrols
Adults with DSM-5 gambling disorder who gambled within the past 2 weeks, excluding those with severe psychiatric comorbidities or recent psychotherapy.
04
Endpoints
Primary
Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling
Secondary
Clinical Global Impression-Improvement Scale
Clinical Global Impression-Severity Scale
Gambling Symptom Assessment Scale
Hamilton Anxiety Rating Scale
Sheehan Disability Scale
Hamilton Depression Rating Scale
Perceived Stress Scale
Quality of Life Inventory
Beyond the preview
Go deeper on NCT02337634.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337634.